玻璃体内注射雷珠单抗治疗早产儿视网膜病变  

Intravitreal injection of ranibizumab for retinopathy of prematurity

作　　者：李松峰[1] 邓光达[1] 刘敬花[1] 马燕[1] 卢海[1] 

机构地区：[1]首都医科大学附属北京同仁医院北京同仁眼科中心,北京市100730

出　　处：《眼科新进展》2016年第7期655-657,共3页Recent Advances in Ophthalmology

基　　金：首都临床特色应用研究项目(编号:Z141107002514029)~~

摘　　要：目的观察玻璃体内注射雷珠单抗治疗早产儿视网膜病变(retinopathy of prematurity,ROP)的疗效及其安全性。方法回顾分析了2012年11月至2014年5月于北京同仁医院治疗的17例(31眼)ROP患儿,在48 h内行玻璃体内注射雷珠单抗,对注射后无反应者,重复玻璃体内注射雷珠单抗或联合激光光凝治疗,术后1 d、1个月内每周随访观察复诊。结果所有治疗眼中,单纯行玻璃体内注射雷珠单抗27眼,玻璃体内注射雷珠单抗联合激光治疗4眼。28眼进行了一次治疗,3眼经过了二次注射治疗;4眼进行补充视网膜激光治疗。所有的ROP治疗均有效,随访期内未见有复发病例。结论玻璃体内注射雷珠单抗对ROP的治疗效果可靠,尤其对于病情严重、全身情况差不能耐受全身麻醉的患儿,其优势明显。Objective To evaluate the effects and safety of intravitreal injection of ranibizumab for retinopathy of prematurity（ ROP）. Methods A retrospective evaluation was performed of medical records. Data from 17 patients（ 31 eyes） of ROP who had been treated with intravitreal injection of ranibizumab in Beijing Tongren Hospital from November 2012 to May2014 were analyzed. All patients were treated with intravitreal injection of ranibizumab within 48 hours after diagnose as ROP. If the infants did not respond positively to the treatment,the additional laser treatment was applied. Follow-up examinations were performed after treatment at postoperative 1 day and 1 month. Results In the all treatment eyes,only treated with intravitreal injection of ranibizumab were in 27 eyes,and intravitreal injection of ranibizumab combined with laser treatment were in 4 eyes. 28 eyes were treated once,3 eyes received the second injection,4eyes were supplemented by laser treatment. All the treatments were effective,and no recurrence was found during the follow-up period. Conclusion The therapeutic effect of intravitreal injection of ranibizumab is reliable,especially for the patients with severe disease,poor general condition not tolerating general anesthesia.

关 键 词：早产儿视网膜病变 玻璃体内注射 雷珠单抗 

分 类 号：R779.7[医药卫生—眼科]